Weekly paclitaxel plus trastuzumab in metastatic breast cancer pretreated with anthracyclines-a phase II multipractice study

BACKGROUND: The 3-weekly combination of trastuzumab and paclitaxel has been approved for the treatment of advanced breast cancer based on a large pivotal study. However, mono and combination chemotherapy trials suggest that weekly paclitaxel has a better therapeutic index, especially in the palliati...

Descripción completa

Detalles Bibliográficos
Autores principales: John, Matthias, Hinke, Axel, Stauch, Martina, Wolf, Heiner, Mohr, Benno, Hindenburg, Hans-Joachim, Papke, Jens, Schlosser, Joachim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3443018/
https://www.ncbi.nlm.nih.gov/pubmed/22559145
http://dx.doi.org/10.1186/1471-2407-12-165

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3443018/
https://www.ncbi.nlm.nih.gov/pubmed/22559145
http://dx.doi.org/10.1186/1471-2407-12-165

Ejemplares similares